Sector: Pharmaceutical Preparations · Industry: Biotechnology · Exchange: Nasdaq
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Headquarters: San Diego, CA · Employees: 106 · Website: https://arcturusrx.com
Arcturus Therapeutics Holdings Inc. (ARCT) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Macroplane tracks Arcturus Therapeutics Holdings Inc.'s (ARCT) supply chain. Key suppliers include MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI).
Search companies · Macro trends · Industries · Product categories · Baskets